Blog
RSS FeedPosted by Michael Wonder on 05 Nov 2020
IQWiG publishes a new version of its general methods
5 November 2020 - New features include the investigation of volume-outcome relationships and different mean observation times in clinical studies. ...
Posted by Michael Wonder on 28 Jun 2020
NICE's evaluations of medicines authorized by EMA with conditional marketing authorization or under exceptional circumstances
25 June 2020 - Products which received conditional marketing authorisation or authorisation in exceptional circumstances by European Medicines Agency up to ...
Posted by Michael Wonder on 23 Jun 2020
MHRA extends access to Santhera's DMD drug via the EAMS
23 June 2020 - The UK’s Medicines and Healthcare products Regulatory Agency has renewed for a further year the Early ...
Posted by Michael Wonder on 18 Mar 2020
COVID-19: an update from Dr. Brian O’Rourke, CADTH President and CEO
18 March 2020 - As our country deals with the COVID-19 situation, CADTH has implemented several initiatives to mitigate the ...
Posted by Michael Wonder on 28 Nov 2019
Medicare bill ‘puts every Australian at risk’
28 November 2019 - A new Medicare anti-fraud bill would put the privacy of every Australian at risk and create ...
Posted by Michael Wonder on 23 Oct 2019
Blair had private health insurance — but his cancer treatment still cost almost $1,000 a week
24 October 2019 - It is Anzac Day 2017, and Blair Meldrum cannot get out of bed. ...
Posted by Michael Wonder on 07 Aug 2019
DHB backs PHARMAC in making ‘hard calls’
7 August 2019 - Hauora Tairawhiti has a role of supporting drugs-funding agency PHARMAC in its ‘‘hard calls” but not ...
Posted by Michael Wonder on 07 Aug 2019
PHARMAC considers funding breast cancer drug Kadcyla advocates have been fighting for
7 August 2019 - The Government's drug-buying agency PHARMAC is considering funding three new drugs - including one which advocates ...
Posted by Michael Wonder on 14 Jul 2019
Bev takes 14 pills a day. She's far from alone.
15 July 2019 - She is among the more than one-in-three Australians aged over 70 who take five or more different ...
Posted by Michael Wonder on 23 Jun 2019
Epilepsy medicine worry
24 June 2019 - A controversial change of epilepsy drug funding could see her and thousands of other people with ...
Posted by Michael Wonder on 01 May 2019
PHARMAC sheds a little more light on procedures in savvy political move
1 May 2019 - Steve Maharey has just secured special status on David Clark's Christmas card list. ...
Posted by Michael Wonder on 27 Mar 2019
600 years’ supply of cystic fibrosis drug destroyed in price row
27 March 2019 - Nearly 8,000 packs of Orkambi, the breakthrough medicine for cystic fibrosis, have been destroyed by the ...
Posted by Michael Wonder on 25 Mar 2019
One Canadian payer's experience with biosimilars
25 March 2019 - Much of the discussion about biosimilar uptake revolves around challenges in the United States, but other ...
Posted by Michael Wonder on 14 Jan 2019
Mandatory or voluntary? A sticking point for European HTA
10 January 2019 - The long road to unified European Health Technology Assessment is continuing. ...
Posted by Michael Wonder on 29 Oct 2018
Is 'lowest cost alternative' rapidly becoming the most common main comparator accepted by the PBAC?
29 October 2018 - Further analysis of the first round of Public Summary Documents from the July 2018 PBAC meeting ...